Join

Compare · LMDX vs NYMX

LMDX vs NYMX

Side-by-side comparison of LumiraDx Limited (LMDX) and Nymox Pharmaceutical Corporation (NYMX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LMDX and NYMX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • LMDX is the larger of the two at $2.23B, about 18.7x NYMX ($119.6M).
  • LMDX has more recent analyst coverage (4 ratings vs 0 for NYMX).
MetricLMDXNYMX
Company
LumiraDx Limited
Nymox Pharmaceutical Corporation
Price
$0.02-53.80%
$0.20-19.60%
Market cap
$2.23B
$119.6M
1M return
-
-
1Y return
-
-
Sector
Health Care
Health Care
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
0
0
Recent ratings
4
0
NYMX

Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.

Latest LMDX

Latest NYMX